Welcome to our dedicated page for Forte Biosciences news (Ticker: FBRX), a resource for investors and traders seeking the latest updates and insights on Forte Biosciences stock.
Forte Biosciences, Inc. (NASDAQ: FBRX) is a clinical-stage biopharmaceutical company whose news flow centers on the development of its lead program, FB102. The company describes FB102 as a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications, and its press releases focus on clinical progress, financial updates and capital-raising activities related to this program.
News about Forte Biosciences frequently covers clinical trial milestones for FB102, including a phase 2 trial in celiac disease and phase 1b trials in vitiligo and alopecia areata. The company has issued releases discussing positive phase 1b data in celiac disease, additional data presentations at scientific meetings, and expectations for future clinical readouts. These updates provide insight into how Forte interprets emerging data for FB102 across multiple autoimmune indications.
Investors following FBRX can also see quarterly financial results reported via press releases that summarize research and development spending, general and administrative expenses and net loss, along with references to the company’s Form 10-Q filings. Other regular news items include public offering announcements, such as the pricing of common stock and pre-funded warrant offerings, and equity inducement grants made under Forte’s inducement equity incentive plan for new employees, as required by Nasdaq listing rules.
In addition, Forte issues notices about conference presentations at healthcare and investor events where management discusses FB102 and the company’s clinical strategy. Together, these news items offer a view into Forte’s clinical development timeline, financing approach and corporate activities for those researching Forte Biosciences and its FBRX stock.
Forte Biosciences, Inc. (NASDAQ: FBRX) announces the approval of an equity inducement award under NASDAQ rules, granting 25,000 shares of common stock to a new non-executive employee. The award vests over four years, with 25% vesting after the first year and the remainder in monthly increments. This inducement aims to attract talent in a competitive market. Forte is advancing its lead product, FB-401, for inflammatory skin diseases, having initiated a Phase 2 trial to address unmet needs in pediatric and adult patients with atopic dermatitis.
Forte Biosciences, Inc. (NASDAQ: FBRX) announced that CEO Paul Wagner, Ph.D., will present at the Stifel 2020 Virtual Healthcare Conference on November 18, 2020, from 2:40 to 3:10 PM ET. A webcast of the presentation will be accessible via Forte’s website and will remain available until November 25th. The company is focused on developing FB-401, a live biotherapeutic for inflammatory skin diseases, particularly atopic dermatitis. The drug has completed Phase 1/2a trials and a new multi-center trial is expected to enroll patients from age 2 and older.
Forte Biosciences, Inc. (NASDAQ: FBRX) reported significant advancements in its third quarter 2020 financial results. The company initiated a randomized clinical trial for FB-401 aimed at treating atopic dermatitis, with FDA granting Fast Track designation. Financially, Forte ended the quarter with approximately $20.2 million in cash, sufficient for the next 12 months, following a $46 million public offering post-quarter. Research and development expenses rose substantially, reflecting increased clinical development efforts. The net loss for the quarter was $5.1 million.
Forte Biosciences, Inc. (NASDAQ: FBRX) will announce its third quarter 2020 results after market close on November 9, 2020, followed by a conference call at 4:30 PM ET. The call will discuss the results and provide a business update. Forte is developing FB-401, a treatment for inflammatory skin diseases, currently in a multi-center clinical trial that includes pediatric, adolescent, and adult subjects aged 2 and older. The trial addresses a significant unmet need for effective therapies in pediatric atopic dermatitis.
Forte Biosciences, Inc. (NASDAQ: FBRX) has successfully closed its underwritten public offering, issuing 1,614,035 shares at a price of $28.50 per share, generating gross proceeds of approximately $46.0 million. The offering included 210,526 shares from the underwriters' option. The offering was managed by Ladenburg Thalmann, Truist Securities, and Chardan, with Brookline Capital Markets acting as co-manager. Forte, a clinical-stage biopharmaceutical company, is focused on developing its lead product, FB-401, for inflammatory skin diseases, particularly atopic dermatitis.
Forte Biosciences, Inc. (NASDAQ: FBRX) has announced an underwritten public offering of its common stock with plans to offer an additional 15% to underwriters. Proceeds will support working capital, regulatory approvals, and clinical development of its product candidates. The offering is backed by Ladenburg Thalmann, Truist Securities, and Chardan as joint book-running managers. A shelf registration statement for this offering was filed in May 2018 and is active. There is no assurance regarding completion or terms of the offering.
Forte Biosciences (NASDAQ: FBRX) announced that the FDA has granted Fast Track Designation to its candidate FB-401 for treating atopic dermatitis. FB-401 is a live biotherapeutic using selected strains of Roseomonas mucosa, showing excellent tolerability and significant improvement in clinical trials. The company is currently enrolling participants for further trials. Fast Track designation will facilitate the development and review process, potentially expediting FB-401's availability for patients with this condition.
Forte Biosciences, Inc. (NASDAQ: FBRX) has announced the issuance of an equity inducement award for the purchase of 60,000 shares of common stock to a new non-executive employee. This award is part of NASDAQ requirements and will vest over four years, with 25% vested after one year. Forte is a clinical-stage company focused on developing FB-401, a treatment for inflammatory skin diseases, currently in Phase 2 clinical trials after successful Phase 1/2a testing. The company aims to address the unmet needs of pediatric atopic dermatitis patients.